- Novo Nordisk is now worth more than $566 billion, more than the valuations of Tesla and Visa
- The drug caused a 13 percent drop in body weight in 12 weeks, better than Wegovy
- READ MORE: Only 20% of Ozempic Patients Maintain Full Weight After Stopping
<!–
<!–
<!– <!–
<!–
<!–
<!–
Novo Nordisk, the pharmaceutical giant, has revealed preliminary study results showing its weight-loss pill worked better than blockbuster injections.
Study participants taking the drug, called amyretin, lost 13 percent of their body weight in 12 weeks, surpassing the amount of weight lost with their Wegovy obesity vaccine, which was 6 percent over the same period of time. time.
The groundbreaking results, which have not yet been backed by strict scientific scrutiny, propelled the company to 12th place among the most valuable companies with a valuation of $566 billion, surpassing Tesla and Visa.
The Danish drugmaker, along with Eli Lilly, run what is essentially a duopoly in the obesity drug market, and both have struggled to meet growing demand for their highly effective monthly diet injections.
The obesity pill caused greater weight loss in the same 12-week period as the company’s innovative Wegovy injectable.